<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Avingtrans Plc — News on 6ix</title>
<link>https://6ix.com/company/avingtrans-plc</link>
<description>Latest news and press releases for Avingtrans Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/avingtrans-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e04b78dffbe2df125f08.webp</url>
<title>Avingtrans Plc</title>
<link>https://6ix.com/company/avingtrans-plc</link>
</image>
<item>
<title>Adaptix receives CE Certification</title>
<link>https://6ix.com/company/avingtrans-plc/news/adaptix-receives-ce-certification</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/adaptix-receives-ce-certification</guid>
<pubDate>Tue, 12 May 2026 06:00:00 GMT</pubDate>
<description>Avingtrans plc announced that its subsidiary, Adaptix Limited, has received CE certification for its Adaptix Ortho350 orthopaedic 3D imaging system, a significant milestone that allows for commercialisation in UK and European healthcare markets. This certification confirms the system meets stringent EU and UK safety, health, and environmental requirements, enabling Adaptix to expand its reach beyond its existing veterinary and industrial markets. The Adaptix Ortho350 offers affordable, low-dose </description>
</item>
<item>
<title>Strong Nuclear Orders for Avingtrans</title>
<link>https://6ix.com/company/avingtrans-plc/news/strong-nuclear-orders-for-avingtrans</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/strong-nuclear-orders-for-avingtrans</guid>
<pubDate>Thu, 16 Apr 2026 06:00:00 GMT</pubDate>
<description>Avingtrans plc's Advanced Engineering Systems division has secured over £10 million in nuclear orders since the start of the year, including a £3 million contract for a Reactor Water Cleanup Pump for the Iberdrola Cofrentes Nuclear Power Plant and orders for next-generation nuclear technology prototypes. This strong performance is driven by increased global demand for energy security, decarbonisation, and AI infrastructure, with the company well-positioned to support the entire nuclear lifecycle</description>
</item>
<item>
<title>Scientific Magnetics Ships 20th Quantum Magnet</title>
<link>https://6ix.com/company/avingtrans-plc/news/scientific-magnetics-ships-20th-quantum-magnet</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/scientific-magnetics-ships-20th-quantum-magnet</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>Avingtrans plc's subsidiary, Scientific Magnetics, has successfully shipped its 20th superconducting magnet for quantum computing applications, positioning the company as a key supplier in a rapidly growing sector. This milestone coincides with significant UK government investment in quantum technologies, aiming to create substantial economic impact and jobs. Scientific Magnetics, with its expertise in magnet systems for MRI and scientific research, is well-placed to capitalize on the increasing</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/avingtrans-plc/news/holdings-in-company-975</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/holdings-in-company-975</guid>
<pubDate>Wed, 04 Mar 2026 07:00:00 GMT</pubDate>
<description>BGF Investment Management Limited has reduced its holding in Avingtrans PLC, with its total voting rights now standing at 6.802% as of March 2, 2026, down from a previous notification of 7.408%. This change represents an acquisition or disposal of voting rights, with the total number of voting rights in the issuer being 33,269,322. The notification was made on March 3, 2026, and the full chain of controlled undertakings through which the voting rights are held has been disclosed.
</description>
</item>
<item>
<title>Interim Results</title>
<link>https://6ix.com/company/avingtrans-plc/news/interim-results-467</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/interim-results-467</guid>
<pubDate>Wed, 25 Feb 2026 07:00:00 GMT</pubDate>
<description>Avingtrans PLC reported interim results for the six months ended 30 November 2025, with revenue remaining flat at £78.1m, while gross margin improved to 31.7% and adjusted EBITDA increased by 10.4% to £9.6m, driven by reduced losses in the Medical and Industrial Imaging division. Adjusted profit before tax rose by 27.1% to £5.7m, and adjusted diluted earnings per share increased to 14.6p. The company also saw a stronger cash inflow from operating activities of £7.6m, with net debt unchanged at £</description>
</item>
<item>
<title>Exercise of Options & TVR</title>
<link>https://6ix.com/company/avingtrans-plc/news/exercise-of-options-and-tvr-9</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/exercise-of-options-and-tvr-9</guid>
<pubDate>Tue, 27 Jan 2026 17:42:00 GMT</pubDate>
<description>Avingtrans Plc announced the exercise of 138,900 CSOP options by non-PDMR employees, resulting in the issuance of 138,900 new ordinary shares. These new shares will be admitted to trading on AIM on February 4, 2026. Following this issuance, the company's total issued ordinary share capital will be 33,269,322 shares, with no shares held in treasury. This updated total voting rights figure serves as the denominator for shareholders to determine their notification obligations under the FCA's Disclo</description>
</item>
<item>
<title>Trading Update and Notice of Results</title>
<link>https://6ix.com/company/avingtrans-plc/news/trading-update-and-notice-of-results-86</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/trading-update-and-notice-of-results-86</guid>
<pubDate>Wed, 21 Jan 2026 07:00:00 GMT</pubDate>
<description>Avingtrans plc has announced that trading for the first six months of the financial year to 30 November 2025 was in line with management expectations, with positive momentum continuing across the Group, particularly in AI and Data Centre driven markets, and a resurgence in nuclear power, though significant growth effects are anticipated from FY27. The company is confident in meeting FY26 market expectations and is engaged in positive discussions for contracts likely to commence in FY27. Avingtra</description>
</item>
<item>
<title>Issue of Share Options</title>
<link>https://6ix.com/company/avingtrans-plc/news/issue-of-share-options-9</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/issue-of-share-options-9</guid>
<pubDate>Mon, 12 Jan 2026 17:13:00 GMT</pubDate>
<description>Avingtrans Plc has granted options over 293,000 ordinary shares at an exercise price of 515.0 pence per share to non-PDMR employees under its Share Option Plan. These options are subject to a three-year vesting period and a performance condition requiring adjusted earnings per share growth to at least match the increase in the Retail Prices Index.
Disclaimer*</description>
</item>
<item>
<title>Notification of Major Holdings</title>
<link>https://6ix.com/company/avingtrans-plc/news/notification-of-major-holdings-168</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/notification-of-major-holdings-168</guid>
<pubDate>Mon, 08 Dec 2025 14:34:00 GMT</pubDate>
<description>Avingtrans Plc has announced a notification of major holdings following a sale of 120,000 ordinary shares by the Avingtrans Employees' Share Trust on December 3, 2025. This transaction has reduced the Trust's holding to 990,974 ordinary shares, representing 2.99% of the company's issued ordinary share capital of 33,130,422 shares, falling below the 3% notification threshold.
Disclaimer*</description>
</item>
<item>
<title>Result of AGM - Board Appointment</title>
<link>https://6ix.com/company/avingtrans-plc/news/result-of-agm-board-appointment</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/result-of-agm-board-appointment</guid>
<pubDate>Thu, 27 Nov 2025 13:59:00 GMT</pubDate>
<description>Avingtrans plc announced that all resolutions were passed at its Annual General Meeting, confirming the immediate appointment of Austen Adams as Group Chief Operating Officer. The company stated that its current performance is strong and aligns with market expectations. Austen Adams, aged 60, holds directorships in several companies and currently owns approximately 0.5% of Avingtrans' enlarged share capital, along with options over 330,000 ordinary shares.
Disclaimer*</description>
</item>
<item>
<title>Exercise of Options & PDMR Dealings</title>
<link>https://6ix.com/company/avingtrans-plc/news/exercise-of-options-and-pdmr-dealings-6</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/exercise-of-options-and-pdmr-dealings-6</guid>
<pubDate>Fri, 14 Nov 2025 08:38:00 GMT</pubDate>
<description>Avingtrans PLC announced that on November 13, 2025, Chief Executive Officer Steve McQuillan and Chief Financial Officer Stephen King exercised a total of 591,614 options under the Company's Executive Shared Ownership Plans. Following this, Steve McQuillan now beneficially holds 806,925 ordinary shares, representing 2.44% of the enlarged total voting rights, while Stephen King holds 667,614 ordinary shares, representing 2.02%. These shares were transferred from the Company's Employee Benefit Trus</description>
</item>
<item>
<title>Adaptix receives FDA 510(K) clearance</title>
<link>https://6ix.com/company/avingtrans-plc/news/adaptix-receives-fda-510k-clearance</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/adaptix-receives-fda-510k-clearance</guid>
<pubDate>Mon, 10 Nov 2025 07:00:00 GMT</pubDate>
<description>Avingtrans plc announced that its subsidiary, Adaptix Limited, has received 510(k) clearance from the U.S. Food and Drug Administration for its Adaptix Ortho350, a 3D Digital Tomosynthesis imaging system designed for point-of-care orthopaedic use. This clearance allows Adaptix to enter the substantial U.S. human healthcare imaging market, building on its prior commercial success in veterinary and industrial sectors with similar technology. The Ortho350 offers fast, lower-cost, 3D X-ray imaging w</description>
</item>
<item>
<title>Exercise of Options & Total Voting Rights</title>
<link>https://6ix.com/company/avingtrans-plc/news/exercise-of-options-and-total-voting-rights-54</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/exercise-of-options-and-total-voting-rights-54</guid>
<pubDate>Wed, 01 Oct 2025 15:52:00 GMT</pubDate>
<description>Avingtrans PLC announced the exercise of 40,500 Company Share Option Plan (CSOP) options over ordinary shares of 5p each by certain employees on September 30, 2025, pursuant to the FY 2020 CSOP. Application has been made for admission to trading on AIM for these new ordinary shares, expected to be effective on October 7, 2025. Following this issue, the company will have a total of 33,130,422 ordinary shares in issue and holds no shares in treasury. This figure is to be used by shareholders to de</description>
</item>
<item>
<title>Appointment of Medical Division CEO</title>
<link>https://6ix.com/company/avingtrans-plc/news/appointment-of-medical-division-ceo</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/appointment-of-medical-division-ceo</guid>
<pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
<description>Avingtrans PLC announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses division, which includes Adaptix Ltd and Magnetica Ltd. The appointment is scheduled to take effect on or before March 10, 2026. Gall previously served as Chief Executive Officer of Intelligent Ultrasound Group plc. His experience includes the development and commercialization of medical imaging technologies.
Disclaimer*</description>
</item>
<item>
<title>Preliminary results for the year ended 31 May 2025</title>
<link>https://6ix.com/company/avingtrans-plc/news/preliminary-results-for-the-year-ended-31-may-2025</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/preliminary-results-for-the-year-ended-31-may-2025</guid>
<pubDate>Wed, 24 Sep 2025 06:00:00 GMT</pubDate>
<description>Avingtrans PLC reported preliminary results for the year ended 31 May 2025, featuring a 14.5% increase in revenue from continuing operations to a record £156.4m, up from £136.6m in 2024. The gross margin remained stable at 31.7%. Adjusted EBITDA from continuing operations exceeded expectations at £16.7m, compared to £14.0m in the previous year, with AES division's adjusted EBITDA rising by 20% to £21.5m. Adjusted PBT from continuing operations increased to £8.6m from £7.3m, and adjusted diluted </description>
</item>
<item>
<title>HSBC HOLDINGS PLC ANNOUNCES RESULTS OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES</title>
<link>https://6ix.com/company/avingtrans-plc/news/hsbc-holdings-plc-announces-results-of-its-tender-offers-for-four-series-of-notes-39</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/hsbc-holdings-plc-announces-results-of-its-tender-offers-for-four-series-of-notes-39</guid>
<pubDate>Tue, 09 Sep 2025 10:52:00 GMT</pubDate>
<description>HSBC Holdings plc (the 'Company', 'we' or 'us') today announces the results of its previously announced four separate offers to purchase for cash any and all of the outstanding series of notes listed in the table below. We refer to the outstanding notes listed in the table below collectively as the 'Notes' and separately as a 'series' of Notes. We refer to each offer to purchase a series of Notes as an 'Offer', and collectively as the 'Offers'.</description>
</item>
<item>
<title>Hayward Tyler Secures $16m Nuclear Contracts</title>
<link>https://6ix.com/company/avingtrans-plc/news/hayward-tyler-secures-dollar16m-nuclear-contracts</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/hayward-tyler-secures-dollar16m-nuclear-contracts</guid>
<pubDate>Tue, 02 Sep 2025 06:00:00 GMT</pubDate>
<description>Avingtrans PLC announced that its US subsidiary, Hayward Tyler Inc., secured two new nuclear contracts totaling over $16 million with Korea Hydro & Nuclear Power. The first contract involves supplying complete safety-related pumps for nuclear reactors in South Korea. The second contract is for performance-critical spare parts. Manufacturing will occur at Hayward Tyler's Vermont facility, with completion and delivery expected by the end of FY27. Revenue from these contracts will be primarily reco</description>
</item>
<item>
<title>Booth Industries secures £8.5m HS2 & TfL contracts</title>
<link>https://6ix.com/company/avingtrans-plc/news/booth-industries-secures-pound85m-hs2-and-tfl-contracts</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/booth-industries-secures-pound85m-hs2-and-tfl-contracts</guid>
<pubDate>Thu, 28 Aug 2025 06:00:00 GMT</pubDate>
<description>Avingtrans PLC announced that its subsidiary, Booth Industries, has secured new contracts totaling £8.5 million. The contracts include a deal worth over £7.5 million to supply steel doorsets for HS2's Old Oak Common station over four years. Additionally, Booth Industries has been awarded a multi-year contract with Transport for London to provide maintenance services for the Elizabeth Line tunnel doors, valued at up to £1 million. This follows a previous £4.5 million order from HS2 in January for</description>
</item>
<item>
<title>Trading Update</title>
<link>https://6ix.com/company/avingtrans-plc/news/trading-update-684</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/trading-update-684</guid>
<pubDate>Wed, 28 May 2025 06:00:00 GMT</pubDate>
<description>Trading Update.</description>
</item>
<item>
<title>Booth Industries secures £4.5m Contract</title>
<link>https://6ix.com/company/avingtrans-plc/news/booth-industries-secures-pound45m-contract</link>
<guid isPermaLink="true">https://6ix.com/company/avingtrans-plc/news/booth-industries-secures-pound45m-contract</guid>
<pubDate>Thu, 13 Feb 2025 07:00:00 GMT</pubDate>
<description>Booth Industries secures £4.5m Contract.</description>
</item>
</channel>
</rss>